X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CMS will be responsible for the development and commercialization of INCB54707 (povorcitinib), a selective oral JAK1 inhibitor, which is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma & chronic spontaneous urticaria.
Lead Product(s): Povorcitinib
Therapeutic Area: Dermatology Product Name: INCB054707
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: China Medical System Holdings Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 01, 2024
Details:
INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for adult patients with prurigo nodularis. A Phase 3 trial is being planned for prurigo nodularis.
Lead Product(s): Povorcitinib
Therapeutic Area: Dermatology Product Name: INCB054707
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Details:
Opzelura (ruxolitinib phosphate), a novel topical cream formulation with selective JAK1/JAK2 inhibitor, is in phase 2 trial for the treatment of adults with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.
Lead Product(s): Ruxolitinib Phosphate
Therapeutic Area: Dermatology Product Name: Opzelura
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Details:
INCA034176 (axatilimab) is an investigational monoclonal antibody that targets CSF-1R. It is bein evaluated for the treatment of chronic graft-versus-host disease.
Lead Product(s): Axatilimab
Therapeutic Area: Immunology Product Name: INCA034176
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Syndax Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Under the agreement, Incyte gains exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi (tafasitamab-cxix) and outside of the U.S. as Minjuvi (tafasitamab).
Lead Product(s): Tafasitamab
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: MorphoSys
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2024
Details:
Under the collaboration, AbCellera and Incyte will discover and develop therapeutic antibodies in oncology and Incyte will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 13, 2023
Details:
Syros used its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms, and Incyte received options to obtain worldwide rights to intellectual property resulting from the collaboration for up to 7 validated targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Syros Pharmaceuticals
Deal Size: $189.0 million Upfront Cash: $10.0 million
Deal Type: Termination August 14, 2023
Details:
The collaboration aims to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor, in patients with high risk, resectable cutaneous squamous cell carcinoma.
Lead Product(s): Vusolimogene Oderparepvec,INCB99280
Therapeutic Area: Oncology Product Name: RP1
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Replimune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 31, 2023
Details:
Results showed that patients with AD treated with Opzelura (ruxolitinib) experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment in patients with atopic dermatitis.
Lead Product(s): Ruxolitinib Phosphate
Therapeutic Area: Dermatology Product Name: Opzelura
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
Opzelura (ruxolitinib phosphate), a novel cream formulation, is the first and only topical JAK inhibitor approved for use in the UK indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Lead Product(s): Ruxolitinib Phosphate
Therapeutic Area: Dermatology Product Name: Opzelura
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
